Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage Therapeutics : Wedbush Adjusts Price Target for Sage Therapeutics to $80 From $83, Maintains Outperform Rating

08/03/2021 | 12:46pm EDT


ę MT Newswires 2021
All news about SAGE THERAPEUTICS, INC.
09/23SAGE THERAPEUTICS : Needham Starts Sage Therapeutics at Buy With $84 Price Target
MT
09/21SAGE THERAPEUTICS : Names Chris Benecchi as Chief Commercial Officer
MT
09/21SAGE THERAPEUTICS : Appoints Chris Benecchi as Chief Commercial Officer
BU
09/21Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
CI
09/16SAGE THERAPEUTICS : Receives Fast Track Designation for SAGE-718 for the Treatment of Hunt..
AQ
09/15SAGE THERAPEUTICS : Receives US FDA Fast Track Designation for Potential Huntington's Dise..
MT
09/15SAGE THERAPEUTICS : Receives Fast Track Designation for SAGE-718 for the Treatment of Hunt..
BU
09/15Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Hun..
CI
09/15Sage Therapeutics Gets Fast-Track Designation for Huntington's Disease Treatment
DJ
09/02SAGE THERAPEUTICS : to Present at the Morgan Stanley Global Healthcare Conference
BU
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 7,82 M - -
Net income 2021 -430 M - -
Net cash 2021 1 445 M - -
P/E ratio 2021 -6,19x
Yield 2021 -
Capitalization 2 671 M 2 671 M -
EV / Sales 2021 157x
EV / Sales 2022 12,6x
Nbr of Employees 298
Free-Float 87,6%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 45,42 $
Average target price 83,05 $
Spread / Average Target 82,8%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer & Treasurer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
James Doherty Chief Research Officer
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.-47.50%2 671
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634